Subscribe Us

header ads

Recents

header ads

Cell Therapy Market Size, Growth, Demands Outlook and Forecasts to 2030

Precedence Research - February 02, 2023

According to the research report, the global cell therapy market size is expected to touch USD 60.67 Billion by 2030, from USD 12.59 Billion in 2022, growing with a significant CAGR of 21.72% from 2022 to 2030. 

Cell Therapy Market Size, Statistics | Report 2021 to 2030

The cell therapy report offers a comprehensive study of the current state expected at the major drivers, market strategies, and key vendors’ growth. The report presents energetic visions to conclude and study the market size, market hopes, and competitive surroundings. The research also focuses on the important achievements of the market, research & development, and regional growth of the leading competitors operating in the market. The current trends of the global cell therapy in conjunction with the geographical landscape of this vertical have also been included in this report.

The report offers intricate dynamics about different aspects of the global cell therapy market, which aids companies operating in the market in making strategic development decisions. The study also elaborates on significant changes that are highly anticipated to configure growth of the global cell therapy during the forecast period. It also includes a key indicator assessment that highlights growth prospects of this market and estimates statistics related to growth of the market in terms of value (US$ Mn) and volume (tons).

Sample Link @ https://www.precedenceresearch.com/sample/1700

 Report Scope of the Cell Therapy Market

Report CoverageDetails
Market Size by 2030USD 60.67 Billion
Growth Rate from 2022 to 2030

CAGR of 21.72%

North America Market Share in 202153%
Research Use Segment Market Share in 202161%
Base Year2021
Forecast Period2022 to 2030
Segments CoveredUse Type, Therapy Type, End User, , Geography

This study covers a detailed segmentation of the global cell therapy market, along with key information and a competition outlook. The report mentions company profiles of players that are currently dominating the global cell therapy market, wherein various developments, expansions, and winning strategies practiced and implemented by leading players have been presented in detail.

Key Players

  • Kolon TissueGene Inc.
  • JCR Pharmaceuticals Co. Ltd
  • Castle Creek Biosciences Inc.
  • Anterogen Co. Ltd
  • The Future of Biotechnology
  • Celgene Corporation
  • Tameika Cell Technologies Inc.
  • Cells for Cells
  • MEDIPOST
  • NuVasive Inc.

Market Segmentation

 By Use Type

  • Clinical use
    • By Therapeutic Area
      • Malignancies
      • Muscoskeletal Disorders
      • Autoimmune Disorders
      • Dermatology
      • Cardiovascular
      • Ocular
      • Wounds and injuries
      • Others
    • By Cell Type
      • Stem Cell Therapies
      • BM, Blood, & Umbilical cord-derived Stem Cells
      • Adipose-derived cells
      • Others
    • Non-stem Cell Therapies
  • Research use

By Therapy Type

  • Autologous Therapies
  • Allogenic Therapies

By End User

  • Hospitals
  • Diagnostic centers
  • Clinics
  • Research institutes
  • Regenerative medicine centers
  • Others

By Technology

  • Viral Vector Technology
  • Genome Editing Technology
  • Somatic Cell Technology
  • Cell Immortalization Technology
  • Cell Plasticity Technology
  • Three-dimensional Technology

By Geography

  • North America
    • U.S.
    • Canada
  • Europe
    • U.K.
    • Germany
    • France
  • Asia-Pacific
    • China
    • India
    • Japan
    • South Korea
    • Malaysia
    • Philippines
  • Latin America
    • Brazil
    • Rest of Latin America
  • Middle East & Africa (MEA)
    • GCC
    • North Africa
    • South Africa
    • Rest of the Middle East & Africa

Research Methodology

The research methodology adopted by analysts for compiling the global cell therapy report is based on detailed primary as well as secondary research. With the help of in-depth insights of the market-affiliated information that is obtained and legitimated by market-admissible resources, analysts have offered riveting observations and authentic forecasts for the global market.

During the primary research phase, analysts interviewed market stakeholders, investors, brand managers, vice presidents, and sales and marketing managers. Based on data obtained through interviews of genuine resources, analysts have emphasized the changing scenario of the global market.

For secondary research, analysts scrutinized numerous annual report publications, white papers, market association publications, and company websites to obtain the necessary understanding of the global cell therapy market.

TABLE OF CONTENT

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Cell Therapy Market 

5.1. COVID-19 Landscape: Cell Therapy Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Cell Therapy Market, By Use Type

8.1. Cell Therapy Market, by Use Type, 2022-2030

8.1.1. Clinical use

8.1.1.1. Market Revenue and Forecast (2017-2030)

8.1.2. Research use

8.1.2.1. Market Revenue and Forecast (2017-2030)

Chapter 9. Global Cell Therapy Market, By Therapy Type

9.1. Cell Therapy Market, by Therapy Type, 2022-2030

9.1.1. Autologous Therapies

9.1.1.1. Market Revenue and Forecast (2017-2030)

9.1.2. Allogenic Therapies

9.1.2.1. Market Revenue and Forecast (2017-2030)

Chapter 10. Global Cell Therapy Market, By End User 

10.1. Cell Therapy Market, by End User, 2022-2030

10.1.1. Hospitals

10.1.1.1. Market Revenue and Forecast (2017-2030)

10.1.2. Diagnostic centers

10.1.2.1. Market Revenue and Forecast (2017-2030)

10.1.3. Clinics

10.1.3.1. Market Revenue and Forecast (2017-2030)

10.1.4. Research institutes

10.1.4.1. Market Revenue and Forecast (2017-2030)

10.1.5. Regenerative medicine centers

10.1.5.1. Market Revenue and Forecast (2017-2030)

10.1.6. Others

10.1.6.1. Market Revenue and Forecast (2017-2030)

Chapter 11. Global Cell Therapy Market, By Technology 

11.1. Cell Therapy Market, by Technology, 2022-2030

11.1.1. Viral Vector Technology

11.1.1.1. Market Revenue and Forecast (2017-2030)

11.1.2. Genome Editing Technology

11.1.2.1. Market Revenue and Forecast (2017-2030)

11.1.3. Somatic Cell Technology

11.1.3.1. Market Revenue and Forecast (2017-2030)

11.1.4. Cell Immortalization Technology

11.1.4.1. Market Revenue and Forecast (2017-2030)

11.1.5. Cell Plasticity Technology

11.1.5.1. Market Revenue and Forecast (2017-2030)

Chapter 12. Global Cell Therapy Market, Regional Estimates and Trend Forecast

12.1. North America

12.1.1. Market Revenue and Forecast, by Use Type (2017-2030)

12.1.2. Market Revenue and Forecast, by Therapy Type (2017-2030)

12.1.3. Market Revenue and Forecast, by End User (2017-2030)

12.1.4. Market Revenue and Forecast, by Technology (2017-2030)

12.1.5. U.S.

12.1.5.1. Market Revenue and Forecast, by Use Type (2017-2030)

12.1.5.2. Market Revenue and Forecast, by Therapy Type (2017-2030)

12.1.5.3. Market Revenue and Forecast, by End User (2017-2030)

12.1.5.4. Market Revenue and Forecast, by Technology (2017-2030)

12.1.6. Rest of North America

12.1.6.1. Market Revenue and Forecast, by Use Type (2017-2030)

12.1.6.2. Market Revenue and Forecast, by Therapy Type (2017-2030)

12.1.6.3. Market Revenue and Forecast, by End User (2017-2030)

12.1.6.4. Market Revenue and Forecast, by Technology (2017-2030)

12.2. Europe

12.2.1. Market Revenue and Forecast, by Use Type (2017-2030)

12.2.2. Market Revenue and Forecast, by Therapy Type (2017-2030)

12.2.3. Market Revenue and Forecast, by End User (2017-2030)

12.2.4. Market Revenue and Forecast, by Technology (2017-2030)

12.2.5. UK

12.2.5.1. Market Revenue and Forecast, by Use Type (2017-2030)

12.2.5.2. Market Revenue and Forecast, by Therapy Type (2017-2030)

12.2.5.3. Market Revenue and Forecast, by End User (2017-2030)

12.2.5.4. Market Revenue and Forecast, by Technology (2017-2030)

12.2.6. Germany

12.2.6.1. Market Revenue and Forecast, by Use Type (2017-2030)

12.2.6.2. Market Revenue and Forecast, by Therapy Type (2017-2030)

12.2.6.3. Market Revenue and Forecast, by End User (2017-2030)

12.2.6.4. Market Revenue and Forecast, by Technology (2017-2030)

12.2.7. France

12.2.7.1. Market Revenue and Forecast, by Use Type (2017-2030)

12.2.7.2. Market Revenue and Forecast, by Therapy Type (2017-2030)

12.2.7.3. Market Revenue and Forecast, by End User (2017-2030)

12.2.7.4. Market Revenue and Forecast, by Technology (2017-2030)

12.2.8. Rest of Europe

12.2.8.1. Market Revenue and Forecast, by Use Type (2017-2030)

12.2.8.2. Market Revenue and Forecast, by Therapy Type (2017-2030)

12.2.8.3. Market Revenue and Forecast, by End User (2017-2030)

12.2.8.4. Market Revenue and Forecast, by Technology (2017-2030)

12.3. APAC

12.3.1. Market Revenue and Forecast, by Use Type (2017-2030)

12.3.2. Market Revenue and Forecast, by Therapy Type (2017-2030)

12.3.3. Market Revenue and Forecast, by End User (2017-2030)

12.3.4. Market Revenue and Forecast, by Technology (2017-2030)

12.3.5. India

12.3.5.1. Market Revenue and Forecast, by Use Type (2017-2030)

12.3.5.2. Market Revenue and Forecast, by Therapy Type (2017-2030)

12.3.5.3. Market Revenue and Forecast, by End User (2017-2030)

12.3.5.4. Market Revenue and Forecast, by Technology (2017-2030)

12.3.6. China

12.3.6.1. Market Revenue and Forecast, by Use Type (2017-2030)

12.3.6.2. Market Revenue and Forecast, by Therapy Type (2017-2030)

12.3.6.3. Market Revenue and Forecast, by End User (2017-2030)

12.3.6.4. Market Revenue and Forecast, by Technology (2017-2030)

12.3.7. Japan

12.3.7.1. Market Revenue and Forecast, by Use Type (2017-2030)

12.3.7.2. Market Revenue and Forecast, by Therapy Type (2017-2030)

12.3.7.3. Market Revenue and Forecast, by End User (2017-2030)

12.3.7.4. Market Revenue and Forecast, by Technology (2017-2030)

12.3.8. Rest of APAC

12.3.8.1. Market Revenue and Forecast, by Use Type (2017-2030)

12.3.8.2. Market Revenue and Forecast, by Therapy Type (2017-2030)

12.3.8.3. Market Revenue and Forecast, by End User (2017-2030)

12.3.8.4. Market Revenue and Forecast, by Technology (2017-2030)

12.4. MEA

12.4.1. Market Revenue and Forecast, by Use Type (2017-2030)

12.4.2. Market Revenue and Forecast, by Therapy Type (2017-2030)

12.4.3. Market Revenue and Forecast, by End User (2017-2030)

12.4.4. Market Revenue and Forecast, by Technology (2017-2030)

12.4.5. GCC

12.4.5.1. Market Revenue and Forecast, by Use Type (2017-2030)

12.4.5.2. Market Revenue and Forecast, by Therapy Type (2017-2030)

12.4.5.3. Market Revenue and Forecast, by End User (2017-2030)

12.4.5.4. Market Revenue and Forecast, by Technology (2017-2030)

12.4.6. North Africa

12.4.6.1. Market Revenue and Forecast, by Use Type (2017-2030)

12.4.6.2. Market Revenue and Forecast, by Therapy Type (2017-2030)

12.4.6.3. Market Revenue and Forecast, by End User (2017-2030)

12.4.6.4. Market Revenue and Forecast, by Technology (2017-2030)

12.4.7. South Africa

12.4.7.1. Market Revenue and Forecast, by Use Type (2017-2030)

12.4.7.2. Market Revenue and Forecast, by Therapy Type (2017-2030)

12.4.7.3. Market Revenue and Forecast, by End User (2017-2030)

12.4.7.4. Market Revenue and Forecast, by Technology (2017-2030)

12.4.8. Rest of MEA

12.4.8.1. Market Revenue and Forecast, by Use Type (2017-2030)

12.4.8.2. Market Revenue and Forecast, by Therapy Type (2017-2030)

12.4.8.3. Market Revenue and Forecast, by End User (2017-2030)

12.4.8.4. Market Revenue and Forecast, by Technology (2017-2030)

12.5. Latin America

12.5.1. Market Revenue and Forecast, by Use Type (2017-2030)

12.5.2. Market Revenue and Forecast, by Therapy Type (2017-2030)

12.5.3. Market Revenue and Forecast, by End User (2017-2030)

12.5.4. Market Revenue and Forecast, by Technology (2017-2030)

12.5.5. Brazil

12.5.5.1. Market Revenue and Forecast, by Use Type (2017-2030)

12.5.5.2. Market Revenue and Forecast, by Therapy Type (2017-2030)

12.5.5.3. Market Revenue and Forecast, by End User (2017-2030)

12.5.5.4. Market Revenue and Forecast, by Technology (2017-2030)

12.5.6. Rest of LATAM

12.5.6.1. Market Revenue and Forecast, by Use Type (2017-2030)

12.5.6.2. Market Revenue and Forecast, by Therapy Type (2017-2030)

12.5.6.3. Market Revenue and Forecast, by End User (2017-2030)

12.5.6.4. Market Revenue and Forecast, by Technology (2017-2030)

Chapter 13. Company Profiles

13.1. Kolon TissueGene Inc.

13.1.1. Company Overview

13.1.2. Product Offerings

13.1.3. Financial Performance

13.1.4. Recent Initiatives

13.2. JCR Pharmaceuticals Co. Ltd

13.2.1. Company Overview

13.2.2. Product Offerings

13.2.3. Financial Performance

13.2.4. Recent Initiatives

13.3. Castle Creek Biosciences Inc.

13.3.1. Company Overview

13.3.2. Product Offerings

13.3.3. Financial Performance

13.3.4. Recent Initiatives

13.4. Anterogen Co. Ltd

13.4.1. Company Overview

13.4.2. Product Offerings

13.4.3. Financial Performance

13.4.4. Recent Initiatives

13.5. The Future of Biotechnology

13.5.1. Company Overview

13.5.2. Product Offerings

13.5.3. Financial Performance

13.5.4. Recent Initiatives

13.6. Celgene Corporation

13.6.1. Company Overview

13.6.2. Product Offerings

13.6.3. Financial Performance

13.6.4. Recent Initiatives

13.7. Tameika Cell Technologies Inc.

13.7.1. Company Overview

13.7.2. Product Offerings

13.7.3. Financial Performance

13.7.4. Recent Initiatives

13.8. Cells for Cells

13.8.1. Company Overview

13.8.2. Product Offerings

13.8.3. Financial Performance

13.8.4. Recent Initiatives

13.9. MEDIPOST

13.9.1. Company Overview

13.9.2. Product Offerings

13.9.3. Financial Performance

13.9.4. Recent Initiatives

13.10. NuVasive Inc.

13.10.1. Company Overview

13.10.2. Product Offerings

13.10.3. Financial Performance

13.10.4. Recent Initiatives

Chapter 14. Research Methodology

14.1. Primary Research

14.2. Secondary Research

14.3. Assumptions

Chapter 15. Appendix

15.1. About Us

15.2. Glossary of Terms

Contact Us:

Precedence Research

Apt 1408 1785 Riverside Drive Ottawa, ON, K1G 3T7, Canada

Call: +1 774 402 6168

Email: sales@precedenceresearch.com

Website: https://www.precedenceresearch.com

 Blog: https://www.pharma-geek.com

 

Tags:

Post a Comment

0 Comments